ILMN logo

Illumina, Inc. Stock Price

NasdaqGS:ILMN Community·US$15.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 71 Fair Values set on narratives written by author

ILMN Share Price Performance

US$102.12
-38.54 (-27.40%)
34.8% undervalued intrinsic discount
US$156.51
Fair Value
US$102.12
-38.54 (-27.40%)
44.8% undervalued intrinsic discount
US$185.00
Fair Value
Price US$102.12
AnalystHighTarget US$185.00
AnalystConsensusTarget US$111.95
AnalystLowTarget US$75.00

ILMN Community Narratives

AnalystHighTarget·Updated
Fair Value US$156.51 34.8% undervalued intrinsic discount

NovaSeq X And SomaLogic Will Drive Precision Medicine Despite Challenges

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$111.95 8.8% undervalued intrinsic discount

Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks

0users have liked this narrative
0users have commented on this narrative
39users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$75 36.2% overvalued intrinsic discount

Rising Regulations And Fierce Competition Will Impede Clinical Sequencing

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent ILMN News & Updates

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Aug 31
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 05
Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next

Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit

Jul 09
Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit

Illumina, Inc. Key Details

US$4.3b

Revenue

US$1.4b

Cost of Revenue

US$2.9b

Gross Profit

US$1.7b

Other Expenses

US$1.3b

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
8.17
Gross Margin
68.16%
Net Profit Margin
29.34%
Debt/Equity Ratio
88.2%

Illumina, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and good value.

2 Risks
3 Rewards

About ILMN

Founded
1998
Employees
9000
CEO
Jacob Thaysen
WebsiteView website
www.illumina.com

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›